Study Inclusion Criteria:
- Diagnosis of severe alopecia areata (AA) with 50% scalp hair loss
- No spontaneous scalp hair regrowth over the past 6 months
- Current episode of AA lasting less than 8 years
Study Details:
- AbbVie/Upadacitinib Study
- Age Range: 12-63 years
- Treatment: Oral tablet (Upadacitinib – JAK inhibitor)
- Sanofi/Amlitelimab Study
- Age Range: 18 years and older
- Treatment: Subcutaneous injection (Amlitelimab – monoclonal antibody)
- Additional Requirement: Diagnosis of AA for more than 6 months
CLICK HERE FOR MORE INFORMATION ON HOW TO PARTICIPATE
Thank you for your continued support in our journey towards a cure!